Skip to main content
Registrieren
Springer Medizin
SUCHE
MENÜ 1 2 3 4
main-content
nach oben
Erschienen in: Der Ophthalmologe 6/2019

22.02.2019 | Leitthema

Therapieoptionen bei progredienter Myopie im Kindesalter

verfasst von: Dr. L. Joachimsen, Prof. Dr. W. A. Lagrèze

Erschienen in: Die Ophthalmologie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Weltweit nimmt die Inzidenz der Myopie zu. Die damit einhergehende Zunahme sekundärer und visusbedrohender Augenerkrankungen wird Patienten, Augenärzte, Optometristen, Optiker und die Gesundheitssysteme vor große Herausforderungen stellen. Da eine Myopie im Kindes- und Jugendalter beginnt, kann eine Progression nur in dieser Lebensphase beeinflusst werden. Dieser Beitrag gibt einen Überblick über optische und pharmakologische Therapieoptionen, die mittlere Effektgrößen von bis zu 50 % Progressionsminderung bei vergleichsweise günstigem Nebenwirkungsprofil aufweisen.
Literatur
1.
Fricke TR, Jong M, Naidoo KS, Sankaridurg P, Naduvilath TJ, Ho SM et al (2018) Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. Br J Ophthalmol 102(7):855–862 CrossRef
2.
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P et al (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5):1036–1042 CrossRef
3.
Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJM, Anastasopoulos E et al (2015) Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 122(7):1489–1497 CrossRef
4.
Wesemann W (2018) Analysis of spectacle lens prescriptions shows no increase of myopia in Germany from 2000 to 2015. Ophthalmologe 115(5):409–417 CrossRef
5.
Flitcroft DI (2012) The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res 31(6):622–660 CrossRef
6.
Trier K, Munk Ribel-Madsen S, Cui D, Brøgger Christensen S (2008) Systemic 7‑methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study. J Ocul Biol Dis Infor 1(2–4):85–93 CrossRef
7.
Jensen H (1991) Myopia progression in young school children. A prospective study of myopia progression and the effect of a trial with bifocal lenses and beta blocker eye drops. Acta Ophthalmol 200:1–79
8.
Chua W‑H, Balakrishnan V, Chan Y‑H, Tong L, Ling Y, Quah B‑L et al (2006) Atropine for the treatment of childhood myopia. Ophthalmology 113(12):2285–2291 CrossRef
9.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A et al (2012) Atropine for the treatment of childhood myopia: safety and efficacy of 0.5 %, 0.1 %, and 0.01 % doses (Atropine for the Treatment of Myopia 2). Ophthalmology 119(2):347–354 CrossRef
10.
Chia A, Chua W‑H, Wen L, Fong A, Goon YY, Tan D (2014) Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01 %, 0.1 % and 0.5. Am J Ophthalmol 157(2):451–457.e1 CrossRef
11.
12.
Li S‑M, Wu S‑S, Kang M‑T, Liu Y, Jia S‑M, Li S‑Y et al (2014) Atropine slows myopia progression more in Asian than white children by meta-analysis. Optom Vis Sci 91(3):342–350 PubMed
13.
Schittkowski MP, Sturm V (2018) Atropine for the prevention of progression in myopia—data, side effects, practical guidelines. Klin Monbl Augenheilkd 235(4):385–391 CrossRef
14.
Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H et al (2016) Efficacy comparison of 16 interventions for myopia control in children: a network Meta-analysis. Ophthalmology 123(4):697–708 CrossRef
15.
Polling JR, Eijkemans MJ, Esser J, Gilles U, Kolling GH, Schulz E et al (2009) A randomised comparison of bilateral recession versus unilateral recession-resection as surgery for infantile esotropia. Br J Ophthalmol 93(7):954–957 CrossRef
16.
17.
Wu P‑C, Chuang M‑N, Choi J, Chen H, Wu G, Ohno-Matsui K et al (2018) Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond) 33(1):3–13 CrossRef
18.
Wolffsohn JS, Calossi A, Cho P, Gifford K, Jones L, Li M et al (2016) Global trends in myopia management attitudes and strategies in clinical practice. Cont Lens Anterior Eye 39(2):106–116 CrossRef
19.
Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G et al (2017) Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. Jama Ophthalmol 135(6):624–630 CrossRef
20.
Cooper J, Eisenberg N, Schulman E, Wang FM (2013) Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 90(12):1467–1472 CrossRef
21.
Loughman J, Flitcroft DI (2016) The acceptability and visual impact of 0.01 % atropine in a Caucasian population. Br J Ophthalmol 100(11):1525–1529 CrossRef
22.
Nishiyama Y, Moriyama M, Fukamachi M, Uchida A, Miyaushiro H, Kurata A et al (2015) Side Effects of Low Dose Atropine. Nippon Ganka Gakkai Zasshi 119(11):812–816 PubMed
23.
German EJ, Wood D, Hurst MA (1999) Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J Ocul Pharmacol Ther 15(3):257–269 CrossRef
24.
Chia A, Lu Q‑S, Tan D (2015) Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01 % Eyedrops. Ophthalmology 123(2):391–399 CrossRef
25.
Wu P‑C, Yang Y‑H, Fang P‑C (2011) The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther 27(5):461–466 CrossRef
26.
Sun Y‑Y, Li S‑M, Li S‑Y, Kang M‑T, Liu L‑R, Meng B et al (2017) Effect of uncorrection versus full correction on myopia progression in 12-year-old children. Graefes Arch Clin Exp Ophthalmol 255(1):189–195 CrossRef
27.
Adler D, Millodot M (2006) The possible effect of undercorrection on myopic progression in children. Clin Exp Optom 89(5):315–321 CrossRef
28.
Chung K, Mohidin N, O’Leary DJ (2002) Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res 42(22):2555–2559 CrossRef
29.
30.
Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D et al (2003) A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci 44(4):1492–1500 CrossRef
31.
Li S‑M, Ji Y‑Z, Wu S‑S, Zhan S‑Y, Wang B, Liu L‑R et al (2011) Multifocal versus single vision lenses intervention to slow progression of myopia in school-age children: a meta-analysis. Surv Ophthalmol 56(5):451–460 CrossRef
32.
Lam CSY, Tang WC, Tse DY-Y, Tang YY, To CH (2014) Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol 98(1):40–45 CrossRef
33.
Aller TA, Liu M, Wildsoet CF (2016) Myopia control with bifocal contact lenses: a randomized clinical trial. Optom Vis Sci 93(4):344–352 CrossRef
34.
Bullimore MA (2017) The safety of soft contact lenses in children. Optom Vis Sci 94(6):638–646 CrossRef
35.
Cho P, Cheung S‑W (2017) Protective role of orthokeratology in reducing risk of rapid axial elongation: a reanalysis of data from the ROMIO and TO-SEE studies. Invest Ophthalmol Vis Sci 58(3):1411–1416 CrossRef
36.
Lin H‑J, Wan L, Tsai F‑J, Tsai Y‑Y, Chen L‑A, Tsai AL et al (2014) Overnight orthokeratology is comparable with atropine in controlling myopia. BMC Ophthalmol 14:40 CrossRef
37.
Chen C, Cheung SW, Cho P (2013) Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci 54(10):6510–6517 CrossRef
38.
Lipson MJ, Brooks MM, Koffler BH (2018) The role of orthokeratology in myopia control: a review. Eye Contact Lens 44(4):224–230 CrossRef
39.
Charm J, Cho P (2013) High myopia-partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci 90(6):530–539 CrossRef
40.
Cho P, Cheung SW, Edwards M (2005) The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res 30(1):71–80 CrossRef
41.
Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T (2012) Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci 53(7):3913–3919 CrossRef
42.
Kakita T, Hiraoka T, Oshika T (2011) Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Vis Sci 52(5):2170–2174 CrossRef
43.
Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R (2012) Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci 53(8):5060–5065 CrossRef
44.
Walline JJ, Jones LA, Sinnott LT (2009) Corneal reshaping and myopia progression. Br J Ophthalmol 93(9):1181–1185 CrossRef
45.
Tsukiyama J, Miyamoto Y, Higaki S, Fukuda M, Shimomura Y (2008) Changes in the anterior and posterior radii of the corneal curvature and anterior chamber depth by orthokeratology. Eye Contact Lens 34(1):17–20 CrossRef
46.
Cheung S‑W, Cho P (2013) Validity of axial length measurements for monitoring myopic progression in orthokeratology. Invest Ophthalmol Vis Sci 54(3):1613–1615 CrossRef
47.
Cho P, Cheung SW (2017) Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye 40(2):82–87 CrossRef
48.
Watt KG, Swarbrick HA (2007) Trends in microbial keratitis associated with orthokeratology. Eye Contact Lens 33(6 Pt 2):373–377 (discussion 382) CrossRef
49.
Li S‑M, Kang M‑T, Wu S‑S, Liu L‑R, Li H, Chen Z et al (2016) Efficacy, safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Curr Eye Res 41(5):600–608 CrossRef
50.
Bullimore MA, Sinnott LT, Jones-Jordan LA (2013) The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci 90(9):937–944 CrossRef
51.
Liu YM, Xie P (2016) The safety of orthokeratology—a systematic review. Eye Contact Lens 42(1):35–42 CrossRef
Metadaten
Titel
Therapieoptionen bei progredienter Myopie im Kindesalter
verfasst von
Dr. L. Joachimsen
Prof. Dr. W. A. Lagrèze
Publikationsdatum
22.02.2019
Verlag
Springer Medizin
Erschienen in
Die Ophthalmologie / Ausgabe 6/2019
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-019-0873-7

Weitere Artikel der Ausgabe 6/2019

Der Ophthalmologe 6/2019 Zur Ausgabe

Bild und Fall

Plötzlicher schmerzloser Visusabfall bei einem Neunjährigen

Originalien

Glaukome im stationären Leistungsgeschehen in Deutschland in 2015

Originalien

Morphologische retinale Charakteristika von Patienten mit einer Sehbehinderung infolge eines diabetischen Makulaödems

Leitlinien, Stellungnahmen und Empfehlungen

Stellungnahme von DOG, RG und BVA zur therapeutischen Anwendung von voretigene neparvovec (Luxturna™) in der Augenheilkunde

Originalien

Real-Life-Daten-Analyse der Therapiequalität bei Patienten mit exsudativer altersabhängiger Makuladegeneration (AMD) und venösen Gefäßverschlüssen an einer deutschen Universitätsaugenklinik

Kasuistiken

Panuveitis infektiologischer Genese

Neu im Fachgebiet Augenheilkunde

10.06.2022 | Psychosomatik | CME

Psychosomatik in der Augenheilkunde

09.06.2022 | Lymphome | Leitthema

Klinisches Vorgehen bei intraokulären Lymphomen

31.05.2022 | Lymphome | Leitthema

Standard Operating Procedure (SOP) zur Versorgung von peri- und intraokulären Lymphomen

25.05.2022 | Praxisrelevante Urteile | CME

Patientenaufklärung vor Augenoperationen
» zur Themenseite Augenheilkunde rotated-square

Version: 0.2061.0